<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00051480</url>
  </required_header>
  <id_info>
    <org_study_id>GV-001.005</org_study_id>
    <nct_id>NCT00051480</nct_id>
  </id_info>
  <brief_title>Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer</brief_title>
  <official_title>A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenVec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenVec</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety and feasibility of giving TNFerade™&#xD;
      with 5-FU, Cisplatin and radiation therapy to patients with locally advanced, esophageal&#xD;
      cancer prior to surgical resection. TNFerade™ is a replication deficient (E1, E3 and E4&#xD;
      deleted) adenovirus vector containing the gene for TNF-alpha controlled by a radiation&#xD;
      inducible promoter. This allows the expression of TNF-alpha to be greatest in the area&#xD;
      receiving radiation. TNF-alpha is a potent cytokine that has been shown to have potent&#xD;
      anti-cancer activities but, due to systemic toxicity, could not be delivered at effective&#xD;
      doses. TNFerade™ is a novel way of selective delivery of TNF-alpha to tumor cells.&#xD;
&#xD;
      TNFerade™ will be delivered once a week for five weeks by direct intratumoral injection by&#xD;
      using endoscopy or Endoscopic Ultrasound. 5-FU (1000 mg/m2/day) will be delivered via&#xD;
      continuous infusion for 96 hours during weeks 1 and 4. Cisplatin (75 mg/m2) will be delivered&#xD;
      on Day 1 and Day 29 intravenously. The dose of radiation delivered will be 45 Gy in 1.8 Gy&#xD;
      fractions for 5 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>TNFerade</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  18-75 years for age;&#xD;
&#xD;
          -  Patients with biopsy proven locally advanced adenocarcinoma or squamous cell carcinoma&#xD;
             of the esophagus, stage II, III, who have not received previous treatment and are&#xD;
             considered to have resectable carcinoma;&#xD;
&#xD;
          -  Informed consent;&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70%;&#xD;
&#xD;
          -  Life expectancy greater than 6 months.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Diagnosis of lymphoma of the esophagus;&#xD;
&#xD;
          -  History of other malignancy in the past 2 years except carcinoma in situ of the cervix&#xD;
             or bladder, non-melanomatous skin cancer or localized early stage prostate cancer with&#xD;
             patients continuously disease-free;&#xD;
&#xD;
          -  Previous chemotherapy or radiation for esophageal cancer or previous radiation therapy&#xD;
             to the target field;&#xD;
&#xD;
          -  T4 disease, metastatic (stage IV) disease or confirmed invasion of the bronchial tree;&#xD;
&#xD;
          -  Extension beyond 2 cm into stomach;&#xD;
&#xD;
          -  Liver enzymes &gt;2.0 x ULN (ALT, AST, bilirubin, alkaline phosphatase);&#xD;
&#xD;
          -  Coagulopathy (INR &gt;1.5, PTT ratio &gt;1.5);&#xD;
&#xD;
          -  Renal insufficiency (creatinine &gt;2.0 mg/dL; calculated creatinine clearance &lt;50&#xD;
             ml/min);&#xD;
&#xD;
          -  Significant anemia (hematocrit &lt;28% or hemoglobin &lt;9 g/dL) (may have RBC transfusion),&#xD;
             or thrombocytopenia (platelet count &lt;100,000/μL)l or leukopenia (WBC &lt;3,000/µL; ANC&#xD;
             &lt;1,500 μL);&#xD;
&#xD;
          -  Contraindication to endoscopic or EUS-guided delivery including obstructive lesions&#xD;
             that can not be dilated to pass endoscope;&#xD;
&#xD;
          -  Clinical evidence of active infection of any type, including hepatitis B or C virus;&#xD;
&#xD;
          -  Due to the embryotoxic effects of chemotherapy, pregnant or lactating women, or men&#xD;
             unable or unwilling to practice contraception are excluded;&#xD;
&#xD;
          -  Experimental medications within the last four weeks prior to Day 1;&#xD;
&#xD;
          -  Chronic systemic corticosteriod use (orally or parenterally administered);&#xD;
&#xD;
          -  Significant concurrent medical or psychiatric illness as defined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto VA Health Care Systems</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology, Mary Crowley Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Center for Cancer Prevention and Care</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>January 10, 2003</study_first_submitted>
  <study_first_submitted_qc>January 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2003</study_first_posted>
  <last_update_submitted>May 11, 2011</last_update_submitted>
  <last_update_submitted_qc>May 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Paul Fischer, PhD</name_title>
    <organization>GenVec</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

